ALK is a receptor tyrosine kinase (RTK) first identified in anaplastic large cell lymphoma patients, where ALK translocations led to an aberrant fusion protein with nucleophosmin (NPM) (discussed in more detail below, Morris et al., 1994). The gene discussed is ALK; the disease is anaplastic large cell lymphoma.